Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma.
The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation.
They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches.
Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma.
Guests:
Prof. Dennis Eichenauer: University of Cologne, Germany;
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany
Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia
Host:
Nabil Dorkhom, MD / EHA Head of Education
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe